AVDL
NASDAQ · Pharmaceuticals
Avadel Pharmaceuticals
$21.64
+0.01 (+0.05%)
Financial Highlights (FY 2026)
Revenue
174.47M
Net Income
-50,382,173
Gross Margin
91.0%
Profit Margin
-28.9%
Rev Growth
+96.4%
D/E Ratio
0.48
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 91.0% | 91.0% | 44.9% | 44.9% |
| Operating Margin | -25.1% | -22.6% | 35.3% | 33.2% |
| Profit Margin | -28.9% | -27.4% | 30.0% | 26.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 174.47M | 88.85M | 342.21M | 329.87M |
| Gross Profit | 158.71M | 80.82M | 153.71M | 148.16M |
| Operating Income | -43,739,073 | -20,046,425 | 120.71M | 109.54M |
| Net Income | -50,382,173 | -23,091,080 | 102.70M | 88.69M |
| Gross Margin | 91.0% | 91.0% | 44.9% | 44.9% |
| Operating Margin | -25.1% | -22.6% | 35.3% | 33.2% |
| Profit Margin | -28.9% | -27.4% | 30.0% | 26.9% |
| Rev Growth | +96.4% | +96.4% | -4.7% | +6.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 343.13M | 343.13M | 835.52M | 800.53M |
| Total Equity | 718.89M | 718.89M | 1.38B | 1.39B |
| D/E Ratio | 0.48 | 0.48 | 0.61 | 0.58 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -36,689,765 | -17,749,797 | 141.15M | 147.31M |
| Free Cash Flow | — | — | 87.98M | 76.45M |